AMTZ announces new initiatives to strengthen medtech innovation

Commemorating the birth anniversary of Dr A.P.J. Abdul Kalam, the Andhra Pradesh MedTech Zone (AMTZ) and its research arm, the Kalam Institute of Health Technology (KIHT), have undertaken two new pioneering initiatives that mark a significant stride in India’s MedTech innovation journey.

SVL Bioscience, a startup within AMTZ, has inaugurated its state-of-the-art clean-room facility for the manufacturing of rapid diagnostic kits for dengue, with plans to expand production to cover a wider range of parameters — a move set to revolutionise affordable and rapid diagnostics in India.

Additionally, AMTZ has initiated a Thermoforming Technology Centre, designed to provide large enclosures and custom components for medical device manufacturers, further strengthening India’s precision manufacturing ecosystem.

“We are in the process of enabling a MedTech Capital Fund to support growth-stage MedTech companies and take them towards IPO-readiness. In addition, AMTZ has acquired a World Trade Center (WTC) license, making it the only cluster in India — and the only one globally — to host both a WHO Collaborating Centre and a World Trade Center. This connects us to 392 WTCs across more than 100 countries, expanding India’s MedTech reach through global trade linkages. The aim is clear — to turn scientific success into commercial success,” said Dr Jitendra Sharma, Founder CEO and Managing Director, AMTZ, and Founder Executive Director of Kalam Institute.

Since its inception in 2017, KIHT, an initiative of the Union Government’s Department of Biotechnology, has evolved into a national catalyst for indigenous R&D, evidence-based policy, and affordable innovation in healthcare technology. It has supported the development of over 100 medical technology products and continues to build a robust scientific and commercial ecosystem.

As the scientific ecosystem matures, KIHT and AMTZ are now deepening their focus on commercialization and scale-up. Around 160 companies currently operate within AMTZ, including nearly 30 foreign entities, making it one of the most vibrant and diversified MedTech manufacturing clusters in Asia. This synergy is yielding tangible global impact.